1Kleinknecht D,Landais P,Goldfarb.Drug-associated acute renal failure:a prospective collaborative study of 81 biopsied patients.Adv Exp Med Biol,1987,212:125-128.
2Perazella MA.COX-2 selective inhibitors:Analysis of renal effects.Expert Opin.Drug Saf,2002,1:53-64.
3Perazella MA,Tray K.Selective cyclooxygenase-2 inhibitors:A pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs.Am J Med,2001,111:64 -67.
4Pison R,Ruggenenti P,Remuzzi G.Drug-induced thrombotic microangiopathy:incidence,prevention and management.Drug Saf,2001,24:491 -501.
5Venkat KK,Tkach D,Kupin W,et al.Reversal of cyclosporineassociated hemolytic uremic syndrome by plasma exchange with fresh-frozen plasma replacement in renal transplant recipients.Transplant Proc,1991,23:1256-1257.
6Trimarchi HM,Truong LD,Brennan S,et al.FK506-associated thrombotic microangiopathy:report of two cases and review of the literature.Transplantation,1999,67:539 -544.
7Gibbs WJ,Drew RH,Perfect JR.Liposomal amphotericin B:clinical experience and perspectives.Expert Rev Anti Infect Ther,2005,3:167-181.
8Briguori C,Airoldi F,Morici N,et al.New pharmacological protocols to prevent or reduce contrast media nephropathy.Minerva Cardioangio,2005,53:49 -58.
9Stone GW,McCullough PA,Tumlin JA,et al.Fenoldopam mesylate for the prevention of contrast-induced nephropathy:a randomized controlled trial.JAMA,2003,290:2284-2291.
10Markowitz GS,Appel GB,Fine PL,et al.Collapsing focal segmental glomerulosclerosis following treatment with high dose pamidronate.J Am Soc Nephrol,2001,12:1164-1172.
